The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
August 25, 2017
The Annual Long Range Planning meeting has been canceled due to potential inclement weather from hurricane Irma. We will reschedule the meeting for October. More information will follow. Continue reading
August 8, 2017
Click here to view Dental Hygiene supervision requirement changes effective June 28, 2017 that may impact your profession. Continue reading